90843-31-5

Usage

Uses

Used in Pharmaceutical Industry:
5-ACETYL-2,3-DIHYDROBENZO(B)FURAN is used as a key intermediate for the preparation of tricyclic [1,2,4]triazine 1,4-dioxides, which are hypoxia selective cytotoxins. These compounds have potential applications in cancer therapy, as they selectively target hypoxic cells within tumors, leading to their destruction while sparing healthy cells.
Additionally, 5-ACETYL-2,3-DIHYDROBENZO(B)FURAN is used in the synthesis of N-(1-benzo[1,3]dioxol-5-yl)ethyl-, N-[1-(2,3-dihydro-benzofuran-5-yl)ethyl-, and N-[1-(2,3-dihydro-1H-indol-5-yl)ethylacrylamides. These compounds exhibit KCNQ2 opener activities, which have potential therapeutic applications in the treatment of neurological disorders and chronic pain conditions.

InChI:InChI=1/C10H10O2/c1-7(11)8-2-3-10-9(6-8)4-5-12-10/h2-3,6H,4-5H2,1H3

Upstream product

• 496-16-2 2.3-dihydrobenzofuran 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 1191-99-7 2,3-dihydro-2H-furan 
• 79-04-9 chloroacetyl chloride 
• 57027-75-5 2-(2-Bromoethyl)phenol 
• 64010-12-4 2-bromophenyl 2-chloroethyl ether 

Downstream Products

• 76429-73-7 2,3-dihydrobenzofuran-5-carboxylic acid 
• 97483-11-9 2-(2,3-dihydrobenzofuran-5-yl)acetothiomorpholide 
• 98-86-2 acetophenone 
• 304648-44-0 4-[5-(2,3-dihydro-benzofuran-5-yl)-3-trifluoromethyl-pyrazol-1-yl]-2-hydroxymethyl-benzenesulfonamide 
• 765945-02-6 (R)-3-(2,6-difluorophenyl)-N-[1-(2,3-dihydrobenzofuran-5-yl)ethyl]acrylamide 

Relevant academic research and scientific papers

Facile preparation of 5-alkyl-1-aryltetrazoles with arenes, acyl chlorides, hydroxylamine, and diphenylphosphoryl azide

Successive treatment of arenes with acyl chlorides and AlCl3, the addition of water and removal of solvent, the reaction with NH2OH?HCl and K2CO3, and the reaction with diphenylphosphoryl azide and DBU under warming conditions gave the corresponding 5-alkyl-1-aryltetrazoles efficiently in good to moderate yields. The present method is one-pot transformation of arenes into 5-alkyl-1-aryltetrazoles using the Friedel-Crafts acylation and the Beckmann rearrangement under transition-metal-free conditions.

ANTIBACTERIAL COMPOUNDS

The present invention relates to compounds of general formula (II),to compositions comprising these compounds and to methods of treating Enterobacteriaceae bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Enterobacteriaceae.

Hydrogen bond donor solvents enabled metal and halogen-free Friedel–Crafts acylations with virtually no waste stream

We have developed a metal and halogen-free Friedel–Crafts acylation protocol with virtually no waste stream generation. We propose a hydrogen bonding donor solvent will form a hydrogen bonding network and may provide significant rate enhancement for Friedel–Crafts reactions. Trifluoroacetic acid is one of the strongest H-bond donor solvents, which is also volatile and can be easily recovered by distillation without need for reaction workup. Our protocol is a ‘green’ Friedel–Crafts acylation process: 1) the catalyst can be recovered and reused; 2) using halogen free starting material (carboxylic acids anhydride or carboxylic acids); 3) no need for aqueous reaction work-up; 4) minimum or no waste steam generation.

Synthesis, and antitubercular and antimicrobial activity of 1′-(4-chlorophenyl)pyrazole containing 3,5-disubstituted pyrazoline derivatives

A new series of 1′-(4-chlorophenyl)-5-(substituted aryl)-3′-(substituted aryl)-3,4-dihydro-2H,1′H-[3,4′]bipyrazolyl derivatives (6a-e, 8a-e, 10a-e) have been synthesized, characterized and screened for antimicrobial and antitubercular activity. Among the synthesized compounds, the minimum inhibition concentration of 10e was found to be as low as 1.56 μg ml-1 and that of 10c was 6.25 μg ml-1 as compared to the standard anti-tb drugs pyrazinamide and streptomycin.

A new solvent system (Cyclopentyl methyl ether-water) in process development of darifenacin HBr

Darifenacin is a potent and competitive M3 selective receptor antagonist (M3SRA), and its hydrobromide salt (1) is the active ingredient of pharmaceutical formulations for oral treatment of urinary incontinence. The present work demonstrates an efficient, commercial manufacturing process for darifenacin hydrobromide (1).

SUBSTITUTED ALKYNYL PHENOXY COMPOUNDS AS NEW SYNERGISTS IN PESTICIDAL COMPOSITIONS

A composition comprising an alkynyl phenoxy compound of Formula (I) as a synergist and a pesticidal active ingredient is described, wherein R1 and R2, similar or different, are (C1-C4)alkyl or R1O- an

Substituted alkynyl phenoxy compounds and their uses

An alkynyl phenoxy compound of Formula (I) is described, wherein R1 and R2, similar or different, are (C1-C4)alkyl or R1O- and R2O- together represent a group -O-CH2-O-, -O-CH(CH

CARBINOL DERIVATIVES HAVING CYCLIC LINKER

[Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

[Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R7; each X and Y independently show CH2, C═O, SO2, etc; Z shows CH or N; each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.; R3 shows C1-8 alkyl group; R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R5 and R6 show a hydrogen atom, etc.; L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

SUBSTITUTED PYRROLIDINES

Disclosed herein are substituted pyrrolidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.